The chart showed that the mutation rate of AHNAK was higher in the low CDI group than in the high CDI group, indicating that the low CDI group has a better prognosis (Ghodke et al. 2021) and that immunotherapy may exert a better effect on the low CDI group (Zhao et al. 2021b). This evidence concerns the gene AHNAK and clostridium difficile infection.